Vivos Therapeutics (VVOS) investor relations material

Executive summary

• Revenue grew 35% year-over-year to $5.2 million in Q2 2026, driven by service revenue from the SCN acquisition and new treatment centers, despite a decline in product revenue.

• Strategic pivot from product sales to a service-based, medical provider-focused model, including the SCN acquisition and AIM Detroit formation.

• Expansion of clinical programs, such as pediatric OSA and insomnia/EEG testing, and partnerships with cardiology groups are expected to drive future growth.

• Management anticipates positive cash flow near end of 2026 or early 2027, with significant EBITDA in 2027.

• Net loss widened to $5.5 million for Q2 2026 and $13.3 million for H1 2026, reflecting higher operating expenses and interest costs.

Financial highlights

• Q2 2026 revenue: $5.2 million (up 35% from Q2 2025); H1 2026 revenue: $10.3 million (up 51% from H1 2025).

• Gross margin improved to 57% in Q2 2026 (from 55%); H1 2026 gross margin rose to 58% (from 53%).

• Net loss per share (basic and diluted): $(0.31) for Q2 2026; $(0.81) for H1 2026.

• Cost of sales increased 29% to $2.2 million in Q2 2026, mainly due to higher diagnostic and therapy costs.

• Total liabilities as of June 30, 2026: $28.1 million; accumulated deficit: $138.5 million.

Outlook and guidance

• Management expects recurring revenue streams from remote patient monitoring, CPAP, and EEG/insomnia programs to accelerate in late 2026 and 2027.

• Cardiology partnerships in Arizona and Florida require $800,000–$1 million CapEx each, with revenue expected to begin in Q1–Q2 2027.

• Additional financing is required to sustain operations and maintain Nasdaq compliance; there is no assurance of obtaining such funding.

• Cost-saving measures have been implemented, but positive cash flow has not yet been achieved.